Toth Financial Advisory Corp Boosts Stock Holdings in argenex SE $ARGX

Key Points

• Toth Financial Advisory Corp increased its argenx holdings by 812.4% in the second quarter, ending with 1,323 shares valued at approximately $1.23 million. Institutional investors collectively own 60.32% of ARGX.
• argenx reported quarterly EPS of $7.32, beating the $5.86 analyst consensus, while revenue of $1.54 billion exceeded expectations of $1.45 billion.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $1,056.89, compared with the stock’s reported price of $876.

Toth Financial Advisory Corp lifted its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 812.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,323 shares of the company's stock after buying an additional 1,178 shares during the quarter. Toth Financial Advisory Corp's holdings in argenex were worth $1,227,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ARGX. Valeo Financial Advisors LLC lifted its position in shares of argenex by 5.1% during the second quarter. Valeo Financial Advisors LLC now owns 1,077 shares of the company's stock worth $999,000 after acquiring an additional 52 shares in the last quarter. Trust Point Inc. grew its position in shares of argenex by 10.3% in the second quarter. Trust Point Inc. now owns 503 shares of the company's stock valued at $467,000 after purchasing an additional 47 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of argenex by 11.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 16,531 shares of the company's stock valued at $15,337,000 after purchasing an additional 1,745 shares during the period. GAMMA Investing LLC lifted its holdings in argenex by 24.6% during the 2nd quarter. GAMMA Investing LLC now owns 349 shares of the company's stock worth $324,000 after purchasing an additional 69 shares in the last quarter. Finally, Harbor Investment Advisory LLC lifted its holdings in argenex by 78.3% during the 2nd quarter. Harbor Investment Advisory LLC now owns 1,157 shares of the company's stock worth $1,073,000 after purchasing an additional 508 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

argenex Stock Up 1.3%

NASDAQ ARGX opened at $876.00 on Thursday. The stock's 50-day simple moving average is $882.24 and its two-hundred day simple moving average is $820.70. argenex SE has a twelve month low of $637.04 and a twelve month high of $953.58. The company has a market capitalization of $54.80 billion, a price-to-earnings ratio of 33.64, a PEG ratio of 1.07 and a beta of 0.46.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analysts' expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, equities analysts expect that argenex SE will post 28.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARGX has been the subject of a number of recent analyst reports. Wall Street Zen raised argenex from a "hold" rating to a "buy" rating in a report on Saturday, July 25th. Citigroup raised their price objective on shares of argenex from $1,152.00 to $1,182.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Wells Fargo & Company upped their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an "overweight" rating in a report on Monday, June 1st. Weiss Ratings cut shares of argenex from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, July 23rd. Finally, Bank of America increased their price objective on argenex from $1,016.00 to $1,088.00 and gave the stock a "buy" rating in a research report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,056.89.

argenex Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source